Indeed, mouse tumor models have shown that oncogenic KRAS synergizes with loss of APC in intestinal tumor progression: while APC inactivation results in the formation of benign adenoma only, activation of oncogenic KRAS in combination with APC inactivation results in the growth of invasive adenocarcinomas [47, 48]. This evidence concerns the gene KRAS and intestinal neoplasm.